Skip to main content

Table 11 Cell count measured by LFCM by treatment and visit (ITT)

From: Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients

  

Day 1

Day 3

Day 7

Day 14

Nepafenac group

Mean

39.2

19.8

9.7

6.0

Std

79.2

25.1

11.2

9.8

N

54

54

54

54

Min

0.0

0.0

0.0

0.0

Max

428.7

116.4

52.7

65.3

Placebo group

Mean

40.4

55.3

32.2

24.1

Std

52.8

66.2

37.3

31.4

N

53

54

54

54

Min

0.0

0.0

0.0

0.0

Max

312.2

311.2

177.3

128.0

P value

 

0.8738

<0.0001

0.0107

0.0394

  1. Non-baseline P values are LSMeans by visit; test = repeated measure ANOVA, main effect of treatment P = 0.0011; treatment by visit interaction P = 0.0186; cell count was measured by laser flare cell meter at six sites
  2. Min minimum, Max maximum, Std standard deviation